November2017

FORWARDLOOKINGSTATEMENT
Thispresentationincludesforwardlookingstatements,includingstatementsregardingtheCompanysabilitytoachievethemilestonesandfinancial
projectionsinthe3and1in20plan,including2020revenuesof$560million,AdjustedEPSof$1.00,and$110millioninrevenuesfromnewpain
managementproducts;theCompanysabilitytosustain20%+revenuegrowthoverthelongterm;theCompanysabilitytodeliverP&Lleveragein2017
andbeyond;theCompanysabilitytotransitiontoabiopharmaceuticalcompanyatanacceleratedpace;theCompanyscontinuedabilitytosellexisting
productsunderSection361ofthePHSApriortotheissuanceofaBLA;theCompanysabilitytoexpanditssalesforce;thetiming,results,andpublication
ofclinicalstudies,andthepotentialsafetyandefficacy,andthetimingandresultsofINDs/BLAs;theabilitytoobtain,andpotentialincrementalrevenues
from,incrementalcommercialreimbursementcoverage,includingcoverageforDFUsandVLUs;theabilitytoobtainincrementalbenefitsfromGPOand
IDNcontracts,andthetimingofsuchbenefits;theCompanysabilitysuccessfullytodevelopnewproductsandthetimingand receiptofpendingand
anticipatedregulatoryclearancesandapprovals,thetimingofproductlaunches,thesizeofthemarketsfortheCompanyscurrentandfutureproducts,
andtheshareofsuchmarketsthattheCompanywillbeabletogarner;theCompanysabilitytocontinuetoincreasemarketshare,expandthemarkets
foritsproducts,toexpandinternationally,andthetimingofsuchactions;theCompanysabilitytogrowoperatingroomrevenues,tohireadditionalsales
representatives,tolaunchadditionalproducts,toacquiresynergisticcompaniesorproducts,andtoincreasedemand;andestimated2017revenues.
Forwardlookingstatementsalsomaybeidentifiedbywordssuchas"believe,""except,""may,""plan,""potential,""will,"goal,target,market
opportunityandsimilarexpressions,andarebasedonourcurrentbeliefsandexpectations.

Forwardlookingstatementsaresubjecttosignificantrisksanduncertainties,andwecautioninvestorsagainstplacingunduerelianceonsuchstatements.
Actualresultsmaydiffermateriallyfromthosesetforthintheforwardlookingstatements.Amongtherisksanduncertaintiesthatcouldcauseactual
resultstodiffermateriallyfromthoseindicatedbysuchforwardlookingstatementsincludetherisksthattheCompanymaybeunabletotransitiontoa
biopharmaceuticalcompanyatanacceleratedpace;theCompanymaybeunablesuccessfullytodevelopanticipatednewproducts; thetimingof
anticipatedregulatoryclearancesandapprovalsmaybedelayedordenied;adverseregulatoryactionsagainsttheCompany;the marketsforthe
CompanyscurrentandfutureproductsmaynotbeaslargeastheCompanyprojectsorgrowasanticipated;theCompanymaynot be abletoachievethe
marketshareitanticipates;theCompanymayfacemoreandmoreeffectivecompetition,theCompanymaynotcontinuetoachievesignificantprocess
improvementsandefficiencies;theCompanymaybeunabletoachievethemilestonesandfinancialprojectionsinthe3and1in20plan;market
demandfortheCompanysproductsmaynotgroworcoulddecline;unexpectedconcernsmayarisefromadditionaldataoranalysisfromourclinical
trials;regulatorysubmissionsmaytakelongerorbemoredifficulttocompletethanexpected;andthatregulatoryauthoritiesmayrequireadditional
informationorfurtherstudiesormayfailtoapproveormaydelayapprovalorgrantmarketingapprovalthatisdifferentthananticipated;andwemaybe
unabletohiretheexpectednumberofsalesrepresentativesonatimelybasis.ForadditionalrisksthatmightaffecttheCompany,pleasereviewtheRisk
FactorssectionofourmostrecentannualreportorquarterlyreportfiledwiththeSecuritiesandExchangeCommission.Anyforwardlookingstatements
speakonlyasofthedateofthispressreleaseandweassumenoobligationtoupdateanyforwardlookingstatement.

2
 INVESTMENTHIGHLIGHTS

GlobalCompanyDeliveringInnovativePlacentalTissueBasedRegenerative
TherapiesandTherapeuticBiologicsthatRestoreFunctionandImproveQuality
ofLife
OpportunitytouseaProductUnderthe361RegulationsbeforeConductinga
BLATrialProvidesUniqueClinicalTrialandRevenueBenefits

3and1in20StrategicPlanTriples2015Revenuesto$560MandDelivers
$1.00ofAdjustedEarningsin2020

Sustain20%+RevenueGrowthOvertheLongTerm

>85%GrossMarginsandStrongBalanceSheet

DeliverP&LLeveragein2017andBeyond

FromInceptiontoSeptember30,2017,Executed$100MofShareRepurchases
ProgramSizehasbeenIncreasedto$120M

3
 COMPANYHIGHLIGHTS

5InnovativeTechnologyPlatforms

Over100*IssuedandAllowedPatents

ProprietaryPurionProcessedPlacentalTissueAllograftContainsaMilieu
of220Proteins(GrowthFactors,ChemokinesandCytokines)

IndustryLeaderintheAmnioticandPlacentalTissueMarket

EmergingLeaderintheSurgicalandOrthoBiologicsMarket

In2020CompleteTransitiontoaBiopharmaceuticalCompany
ExistingProductsRemainRegulatedthroughSection361ofPHSA
NewProductsRegulatedthroughSection351ofPHSAunderIND/BLA
PainManagement,RespiratoryDiseaseandCardiovascularDiseaseareLarge
BiopharmaceuticalOpportunities

*ownedandlicensed

4
 EXPERIENCEDMANAGEMENTTEAM
ParkerH.PetePetit WilliamC.Taylor MichaelJ.Senken AlexandraO.Haden
Chairman&CEO President&COO ChiefFinancialOfficer GeneralCounsel
ThorntonA.Kuntz DeborahL.Dean ChristopherM.Cashman MarkE.Diaz
SeniorVicePresident, ExecutiveVicePresident ExecutiveVicePresident & SeniorVicePresident,
HR&Administration Chief CommercializationOfficer CommercialOperations
ScottM.Turner MichaelW.Carlton KevinD.Lilly MarleneM.DeSimone
SeniorVicePresident, SeniorVicePresident, SeniorVicePresident, Senior VicePresident,
Operations&Procurement Global Sales Sales Marketing
Dr.Rebeccah Brown Dr. DonaldE.Fetterolf Dr. ThomasJ.Koob Dr.I.MarkLandy
VicePresident, ChiefMedicalOfficer ChiefScientificOfficer SeniorVicePresident,
GlobalRegulatoryAffairs StrategicInitiatives
Dr.GloriaMatthews
SeniorVicePresident,
ResearchandDevelopment

5
 DELIVERINGCONSISTENTSUSTAINABLEGROWTH

27ConsecutiveQuartersofSequentialRevenueGrowth
MetorExceededRevenueGuidancein26ofLast27Quarters

90

80

70

60
$s Millions

50

40

30

20

10

6
 2017GROWTHDRIVERS

2016NewProductLaunches:EpiCord,AmnioFill,OrthoFloLyo
ContinuedSalesForceExpansion
ClinicalTrialResultsandPublications
IncrementalCommercialReimbursementCoverageforDFUandVLU
InternationalExpansion
ContinuedLeverageofGPO/IDNContracts
5GroupPurchasingOrganizations(GPO)contractsinplace
4have80%orsolecommitmenttiersforAmnioticTissue/SkinSubstitute
Coversapproximately4,000hospitals
40IntegratedDeliveryNetworks(IDN)Contracts
Coversapproximately1,300hospitals
ManyhavecommittedAmnioticTissueContracts

7
 5YEARSTRATEGICPLAN:3AND1IN20

In2020:Triple2015Revenue,Deliver$1.00 ofAdjustedEPS
andCompleteTransitiontoa BiopharmaceuticalCompany

2020Assumptions
OrganicRevGrowth
*EBITDA30%
Tax36%

$187M $560M**

**NumberCommunicatedtothe
Street.InternalPlanisMuchHigher

WoundCare OperatingRoom PainManagement

*Adjusted
8
 U.S.WOUNDBIOLOGICSMARKETIN2020

2020Skin/DermalSubstitute(SDS)SegmentSalesEstimate$1.1B
2020AmnioticTissueShareEstimate58%vs.29%in2014
2016SDSSalesEstimate$681Mup16%vs.2015
2016MiMedxAmnioticTissueShare63%

10%
21% 18%

39%
2015SDSSegment 2016SDSSegment 45% 2020SDSSegment
27%

$587M $681M $1.1B 58%

32%
34% 5%
6%
6%

AmnioticTissue Allografts Xenografts CellBasedBioengineering

SmartTRAKBusinessIntelligenceand
CompanyEstimates
9
 WOUNDCAREGROWTHTARGET:5YR20%CAGR

WoundCareGrowthDrivers

1. ContinueToTakeMarketShare
LeverageSafetyAdvantageofTerminalSterilization
ExpandScientificandClinicalBodyofEvidence
IncreaseLivesUnderCoverage
BroadenReachInIDN/GPOContracts
NewProducts
NewSettings,LongtermCare(LTAC)

2. ExpandTheMarket
SecondaryCityExpansion
ConvertPhysiciansthatdonot
useAWCProducts
InfluenceandImproveReferral
Patterns
WoundCare OperatingRoom PainManagement

3. InternationalExpansion

10
 CHRONICWOUNDMARKETISUNDERPENETRATED

1.4MChronicDFU/VLUWounds $3BMktOpportunityAlone
2015
2016U.S.MarketFacts 6.5MUSPatientshave
ChronicWounds
AnnualCostofTreatingChronicWounds
intheU.S.is$25Billion
Skin/DermalSubstitutesistheLargest
Segmentat$681Million 3Marenon
MiMedxistheMarketLeaderat31%
healingwounds
SalesofPlacentaDerived/AmnioticTissue
ProductsGrew33%to$305M
MiMedxistheMarketShareLeaderat63%
Under200KareTreatedwith
a SkinorDermalSubstitute

SmartTRAKBusinessIntelligence

11
 EPIFIXVLUMULTICENTERTRIAL
FINALANALYSIS
VLU:EpiFixvs.Control%SubjectsCompleteWound VLU:Apligraf vs.Control%SubjectsComplete
Closure WoundClosure
100% 100%

80% 71% 80%

60% 57%
60% 60%
44% 40%
35% 35% 37%
40% 40% 29%
24%
17% 19% 19%
20% 20% 9% 5%
7%
0% 0%
Week4 Week8 Week12 Week16 Week4 Week8 Week12 Week24

EpiFix(N=52) Control(N=57) Apligraf(N=130) Control(N=110)

EpiFixvs.ApligrafVLUStudyResults
Note:TheMiMedx 100%
ControlwasMore
80% 71%
Efficaciousthanthe 60% 57%
60%
ApligrafControl
35% 37%
40% 29%
Pleasenote:Apligraf andEpiFix studiesare 17%
20% 9%
independentofoneanother
Controls:MultiLayerCompression
Apligraf Reference:PMASupplement
0% TherapywithEpiFix NuDerm Alginate
(P950032)approvaldated05/22/1998
Week4 Week8 Week12 Week16 Week24 Apligraf MoistGauzewithZincPaste
EpiFixReference:PublishedFinalData
Report,ReportedPressRelease08/31/2017
EpiFix(N=52) Apligraf(N=130)

12
 VLUCOMMERCIALINSURANCE
COVERAGEIMPACTMODEL
ONLY33%ofCommercialPayersCoverEpiFix ForBothDFUandVLU

Total EpiFixCommercialLivesDFU/VLU 198,000,000

CurrentlyUncovered VLU(67%) 132,955,205
VLUPrevalenceRate 0.183%*
AdditionalVLUPatientswhenCovered 243,696
EpiFixAveragePrice $1,000
MarketPenetration
#ofApplications 5% 10.0% 15.0% 20.0% 25.0% 30.0%
1 $12,184,780 $24,369,560 $36,554,340 $48,739,119 $60,923,899 $73,108,679

2 $24,369,560 $48,739,119 $73,108,679 $97,478,239 $121,847,799 $146,217,358

3 $36,554,340 $73,108,679 $109,663,019 $146,217,358 $182,771,698 $219,326,038

4 $48,739,119 $97,478,239 $146,217,358 $194,956,478 $243,695,597 $292,434,717

5 $60,923,899 $121,847,799 $182,771,698 $243,695,597 $304,619,497 $365,543,396

*Under65Truven Data
13
 SDSCOMPETITIVEPRODUCTCOMPARISON

ApligrafandDermagraftareregisteredtrademarksofOrganogenesis,Inc.
OmnigraftandPriMatrixareregisteredtrademarksofIntegraLifeSciencesCorporation.AMNIOEXCELisregisteredtrademarkofBioD,LLC,anIntegraLifeSciencescompany.
BIOVANCEisaregisteredtrademarkofAlliquaBiomedical,Inc.
GrafixisregisteredtrademarkofOsirisTherapeutics,Inc.
Referencesprovidedatendofpresentation.
14
 OPERATINGROOMGROWTHTARGET:5YR20%CAGR

OperatingRoomGrowthDrivers

1. IncreaseFootprint
ContinuetoHireDirectSurgicalReps,
Currentlyat30
DeeperPenetrationofGPOandIDN
Contracts

2. ExpandProductLine
NewProductLaunches:
AmnioFill,OrthoFloLYO
SynergisticAcquisitions

3. GrowDemand
PublishClinicalTrialsShowing
ImprovedSurgicalOutcomesand WoundCare OperatingRoom PainManagement
ReducedComplications
IncreaseNumberofVACApprovals

15
 TARGETHIGHVALUESURGICALPROCEDURES

NumberofProcedures(000) AddressableMarketValue($M)
4.3M $5.7B

Orthopedics
Spine,Trauma,Extremities, 2,821
1,528 SportsMedicine

GYN
Hysterectomy,Endometriosis,
$2.9B
1,154 Myomectomy,CSection,Episiotomy 1,000

PLASTICS
HandTendonandNerves,Mohs,
652 ScarRevision,SkinGrafting,Surgical 990
Dehiscence,BreastRecon,Burn
GENERALCOLORECTAL
Bariatric,FistulaRepair,
GIAnastomosis
714 714
UROLOGY
Prostatectomy,PartialNephrectomy,
237 Cystectomy 200

Source:MilleniumResearchGroup,MRGLap2014,ASPSStatistics,MiMedx2015AnnualPlan,MiMedxinternalcodingdata,ManagementEstimates
16
 MUSCULOSKELETALPAINISALARGEOPPORTUNITY

EverydayuseUnder361RegulationsProvidestheOpportunity
toGenerateRevenuewhiletheBLAProcessisOngoing

WoundCare

OperatingRoom

PainManagement

2017 2018 2019 2020 2021

KneeOAPain OutofPocketPay 361ReimbursementOpportunity BLALaunch

PlantarFasciitisPain OutofPocketPay BLALaunch

17
 2015U.S.JOINTPAININJECTIONMARKET

NumberofProcedures

SmartTRAKBusinessIntelligence
andCompanyEstimates
18
 TRANSITIONTOABIOPHARMACEUTICALCOMPANY

AmnioFixInjectable(AI)isourLeadProductCandidate
MicronizedversionofdHACM
CoveredbyourExtensivePlacentalTissueTechnologyPatentFamily
ContainsaMilieuof220+Proteins
IncludesFactorsRequiredforSoftTissueHomeostasisandRepair
AddressMultipleTargetswithaUnifiedMechanismofAction
ProvenSafetyProfile
First3BLAsTargetMusculoskeletalPain
PlantarFasciitis
AchillesTendonitis
OsteoarthriticKneePain
PositiveInterimPhase2BDataValidatesAITherapeuticEffectinTreatingSoft
TissuePain,RestoringFunctionandImprovingQualityofLife
Exiting2020BiopharmaceuticalSalesApproximately20%ofTotalRevenue

19
 PLANTARFASCIITIS:
REPORTEDINTERIMPHASE2BDATA
PrimaryEfficacyEndpoint,PainReliefat3Months:AmnioFixInjectableDemonstrated
ClinicallyMeaningfulandStatisticallySignificantSeparationfromPlacebo(pvalue=0.0001)
StatisticallySignificantResultsWereSeenat6Months(pvalue=0.0005)
AverageReductioninPainfromBaselineat3Monthswas77.5%vs.45.7%forPlacebo
AverageReductioninPainfromBaselineat6Monthswas85.9%vs.57.1%forPlacebo

0%
At3MonthsSubjectsinthePlacebo
10% GroupWereAllowedtoUndergo
AlternativeTherapy
PercentReductionfromBaseline

20%

30%

40%

50%

60%

70%

80%

90%

100%
Baseline 1Month 2Months 3Months 6Months

AmnioFix Saline
20
 OSTEOARTHRITIS(OA)ISABOOMINGEPIDEMIC

OAAffectsanEstimated31MAmericans
ItistheMostCommonformofArthritisandtheLeadingCauseof
DisabilityinAmericanAdults
PrevalenceIncreaseswithAge,Rangingfromabout2%Among
Personsunder45toMoreThan80%AmongThoseOver75

14MAmericansSufferSymptomaticKneeOA
AffectsMoreThan2MPeopleUndertheAgeof45andMore
Than6MPeopleBetweentheAgesof45and64

KneeOAContributesMoreThan$27BillioninU.SHealthCare
ExpendituresAnnually

AstheWorldsPopulationAges,itisEstimatedthatDegenerative
JointDiseasewillImpactOver130MIndividualsGloballyby2050
Source:ArthritisFoundation
21
 ASAFERMOREEFFECTIVEPRODUCTISNEEDED

*
*

* **

*
*
*
**

*Toxicsideeffectsandlimitedefficacy **Limitedefficacy
22
 AMNIOFIXINJECTABLEADDRESSESALLSTAGESOFKNEEOA

23
 PAINMANAGEMENTCLINICALTRIALMILESTONES

20182021:ManagementsEstimation
24
 RESPIRATORYANDCARDIOVASCULARUPDATE

ScanningElectronMicroscope
RespiratorySystem SlidesofRespirableParticles
CompletingDrugDiscoveryand
DesignProcess
InitiatingPreClinicalDevelopment
Program
CurrentGoalistoBeginHuman
Testingin4Q2018

CardiovascularSystem
PublishedSmallAnimalStudy Particlesize
distribution
RefiningDevelopmentProgram
OptimizingDeliverySystem

25
 FINANCIALHIGHLIGHTS

Q32017 Q32016 Change YTD2017 YTD2016 Change

Revenue $84.6M $64.4M +31% Revenue $233.6M $175.1M +33%

GM% 88.7% 87.6% +110bps GM% 88.5% 86.7% +180bps

Adj.GM* 88.7% 88.0% +70bps Adj.GM* 88.5% 87.6% +90bps
R&D% 6.5% 4.5% +200bps R&D% 6.2% 4.9% +130bps
S,G&A 71.2% 74.8% 360bps S,G&A 72.1% 75.1% 300bps
NetInc. $17.5M $3.3M +426% NetInc. $29.9M $6.5M +360%
Adj.NI* $9.5M $6.2M +53% Adj.NI* $25.2M $16.3M +55%
Adj. $15.6M $11.3M +38% Adj. $42.2M $30.5M +38%
EBITDA* EBITDA*

Cashfrom $18.0M $2.8M +531% Cashfrom $42.1M $9.1M +360%

Ops Ops

*ReconciliationofnonGAAPfinancialmeasuresincludedinsupplementalslidessectionoftheslidedeck

26
 FINANCIALHIGHLIGHTS

Revenue
350

300

250

200

150

100

50

0
2014 2015 2016 2017(Est.)
Wound SSO

2017RevenueGuidance=$320.6M $321.6M

27
 KEY2017MILESTONES

PositiveAetnaCoverageDecision
PositiveKaiserCoverageDecision
PresentedGIAnastomosisData
ReleasedPlantarFasciitisPhase2BInterimData

SecondHalf2017
InitiatePivotalBLAPhase3PlantarFasciitisTrial
InitiatePivotalBLAPhase3AchillesTendonitisTrial
InitiateBLAPhase2BOsteoarthritisKneePainTrial
ReportVLUMulticenterData
ReportDFUMulticenterData
PublishGIAnastomosisData
FirstPatentInfringementTrialPossible
AdditionalReimbursementWins

28
 REFERENCES

1. http://www.apligraf.com/professional/pdf/FDAApprovalLetter.pdf
2. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p000036
3. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm480564.htm
4. http://www.prnewswire.com/newsreleases/dermasciencesexpandsaccessofitsamniotictissueproductlinewithnewpremierincagreement
300024252.html
5. http://www.accessdata.fda.gov/cdrh_docs/pdf8/k083440.pdf
6. http://ir.alliqua.com/pressreleases/detail/544/alliquatolaunchbiovancerhumanamnioticmembrane
7. http://investor.osiris.com/annualsproxies.cfm;2011.
8. www.clinicaltrials.gov.Accessed03/01/17.
9. ZelenCM,SerenaTE,DenozireG,FetterolfDE. Aprospectiverandomizedcomparativeparallelstudyofamnioticmembranewoundgraftinthemanagementof
diabeticfootulcers.IntWoundJ.2013Oct;10(5):5027.
10. ZelenCM,SerenaTE,SnyderRJ. Aprospective,randomisedcomparativestudyofweeklyversusbiweeklyapplicationofdehydratedhumanamnion/chorion
membraneallograftinthemanagementofdiabeticfootulcers.IntWoundJ.2014Apr;11(2):1228.
11. ZelenCM,GouldL,SerenaTE,CarterMJ,KellerJ,LiWW. Aprospective,randomised,controlled,multicentrecomparativeeffectivenessstudyofhealingusing
dehydratedhumanamnion/chorionmembraneallograft,bioengineeredskinsubstituteorstandardofcarefortreatmentofchroniclowerextremitydiabetic
ulcers.IntWoundJ.2015Dec;12(6):72432.
12. ZelenCM,SerenaTE,GouldL,LeL,CarterMJ,KellerJ,LiWW. Treatmentofchronicdiabeticlowerextremityulcerswithadvancedtherapies:aprospective,
randomised,controlled,multicentrecomparativestudyexaminingclinicalefficacyandcost.IntWoundJ.2016Apr;13(2):27282.
13. VevesA,FalangaV,ArmstrongDG,SabolinskiML.Graftskin,ahumanskinequivalent,iseffectiveinthemanagementofnoninfectedneuropathicdiabeticfoot
ulcers:aprospectiverandomizedmulticenterclinicaltrial.DiabetesCare.(24)2.2001.pp2905.
14. MarstonW,HanftJ,NorwoodP,Pollak R.TheEfficacyandSafetyofDermagraftinImprovingtheHealingofChronicDiabeticFootUlcers.DiabetesCare,Vol26
#6,June2000.
15. Driver,V.R.,Lavery,L.A.,Reyzelman,A.M.,Dutra,T.G.,Dove,C.R.,Kotsis,S.V.,Kim,H.M.andChung,K.C.(2015),AclinicaltrialofIntegraTemplatefor
diabeticfootulcertreatment.WoundRepandReg,23:891900.doi:10.1111/wrr.12357.
16. SnyderRJ,Shimozaki K,Tallis A,Kerzner M,Reyzelman A,Lintzeris D,BellD,Rutan RL,RosenblumBAProspective,Randomized,Multicenter,Controlled
EvaluationoftheUseofDehydratedAmnioticMembraneAllograftComparedtoStandardofCarefortheClosureofChronicDiabetic FootUlcer.Wounds.2016
Mar;28(3):707.
17. Kavros,S;Dutra,T;GonzalezCruz,R;Liden,B;Marcus,B;McGuire,J;NazarioGuirau,L.TheUseofPriMatrix,aFetalBovineAcellularDermalMatrix,inHealing
ChronicDiabeticFootUlcers:AProspectiveMulticenterStudy.AdvancesinSkin&WoundCare:August2014 Volume27 Issue8 p356362.doi:
10.1097/01.ASW.0000451891.87020.69.
18. Lavery A,etal.TheefficacyandsafetyofGrafix fortreatmentofchronicdiabetesfootulcers:resultsofamulticentre,controlled,randomized,blinded,clinical
trial.IntWoundJ2014;doi:10.1111/iwj.12329.
19. Publicdomain

30
 PLANTARFASCIITISPHASE2BSTUDYOUTLINE

AProspective,SingleBlinded,RandomizedControlledTrialofMicronized
dHACM Injection ComparedtoSalinePlacebo Injection intheTreatmentofPF

PURPOSE ToDetermineWhetherAmnioFix Injectable(mDHACM)isEffectiveintheTreatment

ofRecalcitrantPlantarFasciitis

Randomized,MultiCenter,SingleBlind(Patient)
DESIGN
147PatientswithRecalcitrantPF(ConfirmedDiagnosis>1Monthand<18Months,
VAS>45,ConservativeUsualCare>1Month*)
2ArmUnilateralTreatmentwith:
n=73:Placebo(1mlNormalSaline)
n=74:AmnioFixInjectable(1mlof40mgAI)

PRIMARY MeanChangeinVASScoreBetweenBaselineand3Months
IncidenceofAdverseEventsat12Months

SECONDARY MeanChangeinFunctionalScoreasMeasuredbyFFIRat3Months
ImmunoCompatibilityofFirst20PatientsFollowedinEachArmat3and12Months
LongTermFFIR,VASat6and12 Months
31
*Includinganyofthefollowingmodalities:RICE,SteroidInjection,Stretching,NSAID,Orthotics
 PLANTARFASCIITISPHASE3STUDYOUTLINE

AProspective,DoubleBlinded,RandomizedControlledTrialofMicronized
dHACM Injection ComparedtoSalinePlacebo Injection intheTreatmentofPF

PURPOSE ToDetermineWhetherAmnioFix Injectable(mDHACM)isEffectivein

theTreatmentofRecalcitrantPlantarFasciitis

Randomized,MultiCenter,DoubleBlinded(PatientandReviewer)
DESIGN
164PatientswithRecalcitrantPF(ConfirmedDiagnosis>1Monthand
<18Months,VAS>45,ConservativeUsualCare>1Month*)
2ArmUnilateralTreatmentwith:
n=82:Placebo(1mlNormalSaline)
n=82:AmnioFixInjectable(1mlof40mgAI)

PRIMARY MeanChangeinVASScoreBetweenBaselineand3Months
IncidenceofAdverseEventsat6 Months

SECONDARY MeanChangeinFunctionalScoreasMeasuredbyFFIRat3Months
LongTermFFIRandVASat6Months

*Includinganyofthefollowingmodalities:RICE,SteroidInjection,Stretching,NSAID,Orthotics
32
 ACHILLESTENDONITISPHASE3STUDYOUTLINE

AProspective,DoubleBlinded,RandomizedControlledTrialofMicronized
dHACM Injection ComparedtoSalinePlacebo Injection intheTreatmentofAchillesTendonitis

PURPOSE ToDetermineWhetherAmnioFix Injectable(mDHACM)isEffectiveinthe

TreatmentofAchillesTendonitis

Randomized,MultiCenter,DoubleBlinded(PatientandReviewer)
DESIGN 158patientswithAchillesTendonitis(ConfirmedDiagnosis>1Monthand<18
Months,VAS>45,ConservativeUsualCare>1Month*)
2ArmUnilateralTreatmentwith:
n=79:Placebo(1mlNormalSaline)
n=79:AmnioFixInjectable(1mlof40mgAI)

PRIMARY MeanChangeinVASScoreBetweenBaselineand3Months
IncidenceofAdverseEventsat6 Months

SECONDARY MeanChangeinFunctionalScoreasMeasuredbyFFIRat3Months
LongTermFFIRandVASat6Months

*Includinganyofthefollowingmodalities:RICE,SteroidInjection,Stretching,NSAID,Orthotics
33
 OSTEOARTHRITISPHASE2BSTUDYOUTLINE

AProspective,DoubleBlinded,RandomizedControlledTrialofMicronized
dHACM Injection ComparedtoSalinePlacebo Injection intheTreatmentofOsteoarthritis

PURPOSE ToDetermineWhetherAmnioFix Injectable(mDHACM)isEffectiveinthe

TreatmentofOsteoarthritis

DESIGN Randomized,MultiCenter,DoubleBlinded(PatientandReviewer)
318PatientswithOsteoarthritis(DiagnosisofOsteoarthritis(OA)Definedas
Grade1to3ontheKellgrenLawrenceGradingScale,VAS>45)
2ArmUnilateralTreatmentwith:
n=159:Placebo(1mlNormalSaline)
n=159:AmnioFixInjectable(1mlof40mgAI)

MeanChangeinVASScoreBetweenBaselineand3Months
PRIMARY MeanChangeinWOMAC3.1Score(Pain,StiffnessandPhysicalFunction)
IncidenceofAdverseEventsat12Months

SECONDARY MeanChangeinFunctionalScoreasMeasuredbyKOOSat3Months
LongTermKOOSandVASat12Months
*Includinganyofthefollowingmodalities:RICE,SteroidInjection,Stretching,NSAID,Orthotics
34
 SUPPLEMENTALSLIDE
RECONCILIATIONOFNONGAAP FINANCIALMEASURES
GROSSMARGIN

Three MonthsEnded NineMonthsEnded

September30,2017 September30,2017
2017 2016 2017 2016

GrossMargin(PerGAAP) $75.0M $56.4M $206.6M $151.8M

NonGAAP Adjustments:

OneTimeInventoryCostsIncurredin 0.0M 0.3M 0.2M 1.6M

ConnectionwithAcquisition
GrossMargin BeforeAmortizationof $75.0M $56.7M $206.8M $153.4M
InventoryFairValueStepUp
AdjustedGross Margin 88.7% 88.0% 88.5% 87.6%

35
 SUPPLEMENTALSLIDE
RECONCILIATIONOFNONGAAP FINANCIALMEASURES
NETINCOME
Three MonthsEnded NineMonthsEnded
September30,2017 September30,2017
2017 2016 2017 2016
Net Income(PerGAAP) $17.5M $3.3M $29.9M $6.5M

NonGAAP Adjustments:
TaxRateNormalization* (7.4M) (.5M) (11.4M) (0.9M)
Gain onDivestiture (4.3M) (4.3M)
OneTimeCostsIncurredinConnection 0.2M 1.1M
with Acquisition
OneTimeInventoryCostsIncurredin 0.3M 0.2M 1.6M
ConnectionwithAcquisition
AmortizationofIntangibleAssets 0.4M 0.6M 1.5M 1.9M
SharebasedCompensation 5.3M 4.7M 15.2M 13.8M
EstimatedIncomeTaxImpactfrom (2.0M) (2.4M) (5.9M) (7.7M)
Adjustments
AdjustedNetIncome $9.5M $6.2M $25.2M $16.3M
*Assumesanormalizedtaxrateof42% for2016and35%for2017.
36
 SUPPLEMENTALSLIDE
RECONCILIATIONOFNONGAAP FINANCIALMEASURES
EBITDA
Three MonthsEnded NineMonthsEnded
September30,2017 September30,2017
2017 2016 2017 2016
Net Income(PerGAAP) $17.5M $3.3M $29.9M $6.5M

AddBack:
GainonDivestiture (4.2M) (4.3M)

Income Taxes(Expense)Benefit (4.4M) 1.3M (3.7M) 3.0M

OneTimeCostsIncurredinConnectionwith 0.2M 1.0M

Acquisition
OneTimeInventoryCostsIncurredin 0.3M 0.2M 1.6M
ConnectionwithAcquisition
OtherInterestExpense,Net 0.1M 0.3M 0.3M
DepreciationExpense 1.0M 0.8M 3.1M 2.4M
AmortizationofIntangibleAssets 0.4M 0.6M 1.5M 1.9M
SharebasedCompensation 5.3M 4.7M 15.2M 13.8M
AdjustedEBITDA $15.6M $11.3M $42.2M $30.5M
3737